Nurix Therapeutics Inc (NRIX) FinancialsNRIXNurix Therapeutics Inc

Evaluating the bottom line, Nurix Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 83.12%, while the net margin is 81.69%. These profitability ratios, combined with a Return on Equity (ROE) of 43.99%, provide a clear picture of how effectively NRIX converts its operational activities into shareholder value.

In the context of the broader market, NRIX competes directly with industry leaders such as ADMA and IMNM. With a market capitalization of $2.59B, it holds a leading position in the sector. When comparing efficiency, NRIX's gross margin of 100.00% stands against ADMA's 69.31% and IMNM's N/A. Such benchmarking helps identify whether Nurix Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Nurix has shown impressive financial performance with a significant turnaround in Q3 2026, reporting a net income of 549,807,000 USD and an EPS of 4.73, a remarkable increase from previous losses. The gross margin remains strong at 100%, indicating effective cost management.